Dmitry Baturin
Concepts (63)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pyrimidines | 4 | 2017 | 378 | 0.330 |
Why?
| Pyrazoles | 3 | 2017 | 364 | 0.310 |
Why?
| Interleukin-12 | 1 | 2019 | 110 | 0.160 |
Why?
| Calcineurin | 1 | 2019 | 89 | 0.160 |
Why?
| Interferon-alpha | 1 | 2019 | 187 | 0.150 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 64 | 0.150 |
Why?
| Recombinational DNA Repair | 1 | 2017 | 9 | 0.150 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1361 | 0.140 |
Why?
| Phthalazines | 1 | 2017 | 38 | 0.140 |
Why?
| Gene Knockdown Techniques | 2 | 2019 | 299 | 0.140 |
Why?
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 16 | 0.130 |
Why?
| Piperazines | 1 | 2017 | 311 | 0.120 |
Why?
| Down Syndrome | 1 | 2019 | 338 | 0.120 |
Why?
| Calcineurin Inhibitors | 1 | 2014 | 58 | 0.110 |
Why?
| Fusion Proteins, bcr-abl | 1 | 2014 | 61 | 0.110 |
Why?
| DNA Repair | 1 | 2015 | 186 | 0.110 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 95 | 0.110 |
Why?
| Leukemia, Myeloid, Acute | 2 | 2017 | 536 | 0.110 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2013 | 82 | 0.110 |
Why?
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 25 | 0.110 |
Why?
| Transduction, Genetic | 1 | 2013 | 113 | 0.100 |
Why?
| Cell Line, Tumor | 5 | 2019 | 2725 | 0.100 |
Why?
| Apoptosis | 3 | 2017 | 2369 | 0.100 |
Why?
| Pyrimidinones | 3 | 2017 | 88 | 0.090 |
Why?
| Protein-Tyrosine Kinases | 1 | 2013 | 398 | 0.090 |
Why?
| Hematopoietic Stem Cells | 1 | 2013 | 345 | 0.090 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2013 | 447 | 0.090 |
Why?
| Cell Cycle Proteins | 1 | 2013 | 552 | 0.080 |
Why?
| Drug Synergism | 3 | 2015 | 316 | 0.080 |
Why?
| Nuclear Proteins | 1 | 2013 | 592 | 0.080 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2017 | 706 | 0.080 |
Why?
| Flow Cytometry | 3 | 2019 | 1086 | 0.080 |
Why?
| Mice | 6 | 2019 | 14916 | 0.060 |
Why?
| Animals | 6 | 2019 | 31761 | 0.040 |
Why?
| Tumor Escape | 1 | 2019 | 36 | 0.040 |
Why?
| Mice, Inbred C57BL | 2 | 2019 | 4710 | 0.040 |
Why?
| Female | 6 | 2019 | 59486 | 0.030 |
Why?
| Cytarabine | 1 | 2015 | 52 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2019 | 1044 | 0.030 |
Why?
| DNA Damage | 1 | 2017 | 357 | 0.030 |
Why?
| Dasatinib | 1 | 2014 | 46 | 0.030 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 689 | 0.030 |
Why?
| Thiazoles | 1 | 2014 | 110 | 0.030 |
Why?
| Cyclosporine | 1 | 2014 | 161 | 0.030 |
Why?
| Cell Cycle Checkpoints | 1 | 2013 | 85 | 0.030 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2019 | 965 | 0.030 |
Why?
| Thioguanine | 1 | 2013 | 19 | 0.030 |
Why?
| Antigens, CD34 | 1 | 2013 | 89 | 0.030 |
Why?
| Humans | 7 | 2019 | 114716 | 0.030 |
Why?
| Umbilical Cord | 1 | 2013 | 80 | 0.030 |
Why?
| Drug Resistance | 1 | 2013 | 158 | 0.030 |
Why?
| Disease Progression | 1 | 2019 | 2384 | 0.030 |
Why?
| Myeloid Cells | 1 | 2013 | 127 | 0.020 |
Why?
| Cytokines | 1 | 2019 | 1843 | 0.020 |
Why?
| Lymphocytes | 1 | 2013 | 332 | 0.020 |
Why?
| Cell Proliferation | 1 | 2017 | 2196 | 0.020 |
Why?
| Drug Resistance, Neoplasm | 1 | 2013 | 642 | 0.020 |
Why?
| Protein Kinase Inhibitors | 1 | 2014 | 795 | 0.020 |
Why?
| Cell Line | 1 | 2013 | 2639 | 0.020 |
Why?
| Middle Aged | 2 | 2019 | 26746 | 0.020 |
Why?
| Adult | 2 | 2019 | 30543 | 0.020 |
Why?
| Male | 2 | 2019 | 55558 | 0.010 |
Why?
| Treatment Outcome | 1 | 2014 | 9089 | 0.010 |
Why?
|
|
Baturin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|